Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2026-05-18 Interim / Quarterly Rep…
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q1 2026
2026-05-18 English
POS AM - ABVC BIOPHARMA, INC. (0001173313) (Filer)
Regulatory Filings
2026-03-27 English
ABVC BioPharma Reports 2025 Form 10-K
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the filing of the company's Annual Report (Form 10-K). It provides a summary of financial highlights and strategic updates but is clearly a news dissemination piece (indicated by 'News Details', 'Corporate News', and 'Dissemination of a Corporate News' tags) rather than the full 10-K report itself. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA). FY 2025
2026-03-03 English
10-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
Annual Report FY 2025
2026-03-03 English
10-Q/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
Interim / Quarterly Report Q3 2025
2026-03-03 English
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by ABVC BioPharma, Inc. It includes disclosures about the company's financial results announcement for the fiscal year ended December 31, 2025, and a restatement of previously issued quarterly financial statements due to errors in revenue recognition and fair value measurement. The document discusses the non-reliance on prior financial statements and the company's intention to file an amendment to the prior 10-Q filing. It also mentions a material weakness in internal controls to be disclosed in the upcoming Annual Report on Form 10-K for the year ended December 31, 2025. The document is primarily an announcement of financial results and restatement issues, not the full annual report itself. The presence of a press release as an exhibit further supports that this is a current report announcing financial results and related matters. Therefore, the filing type is a Regulatory Filing (RNS) as it does not contain the full annual report or detailed financial statements but rather disclosures about financial restatements and results announcements.
2026-03-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.